Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
This grant funds early-stage, highly innovative technology development for improving analysis and handling of biospecimens in basic or clinical cancer research, focusing on proof-of-concept studies.
Browse similar grants
Funder: National Institutes of Health
Due Dates: November 10, 2026 (Full application submission deadline)
Funding Amounts: Up to $150,000 per award; approximately $5.1 million total program funding; ~20 awards expected.
Summary: Supports early-stage, proof-of-concept development of innovative technologies for molecular or cellular characterization of cancer or improved biospecimen handling in cancer research.
Description
This funding opportunity, issued by the National Cancer Institute (NCI), seeks applications for the early-stage development of innovative technologies that enable new capabilities in the molecular or cellular characterization of cancer, or that improve the handling and quality control of biospecimens for basic, clinical, or epidemiological cancer research. The grant supports R61 projects focused on proof-of-concept or pilot studies to test the technical feasibility of novel methods, tools, assays, platforms, or instruments relevant to cancer research. Proposed technologies should be cancer-focused, with broad potential applicability, but projects that simply apply existing technologies to new biological or clinical questions are not responsive to this solicitation.
